You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

PALYNZIQ Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: PALYNZIQ
High Confidence Patents:0
Applicants:1
BLAs:1
Pharmacology for PALYNZIQ
Established Pharmacologic ClassPhenylalanine Metabolizing Enzyme
Chemical StructurePhenylalanine Ammonia-Lyase
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PALYNZIQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PALYNZIQ Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PALYNZIQ Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: PALYNZIQ

Introduction

PALYNZIQ (pegvaliase) is a groundbreaking biologic drug developed by BioMarin Pharmaceutical for the treatment of phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine. This article delves into the market dynamics and financial trajectory of PALYNZIQ, highlighting its approval, market performance, and future prospects.

Regulatory Approval and Launch

PALYNZIQ received FDA approval in May 2018 for the treatment of adults with PKU who have uncontrolled blood phenylalanine concentrations greater than 600 micromol per liter on existing management regimens. This approval marked a significant milestone for BioMarin, expanding its portfolio of rare disease treatments[1].

Market Position and Competition

PALYNZIQ entered a market where BioMarin's Kuvan (sapropterin dihydrochloride) was the only FDA-approved treatment for PKU. However, Kuvan faced looming generic competition, which made the launch of PALYNZIQ timely. PALYNZIQ is positioned as a premium product with a wholesale acquisition cost of $192,000, significantly higher than Kuvan[1].

Financial Performance

Since its launch, PALYNZIQ has shown promising financial performance. In the fourth quarter of 2019, PALYNZIQ net product revenues increased by $23.6 million, driven by patients achieving maintenance dosing and new patients initiating therapy. By the end of 2019, 762 patients were on reimbursed PALYNZIQ, with an additional 143 naïve patients awaiting their first injection[3].

In 2022, PALYNZIQ net product revenues continued to grow, with a 9% increase year-over-year, reaching $66.2 million for the third quarter. For the full year, revenues stood at $182.7 million, a 5% increase from the previous year[2].

Market Share and Growth Prospects

PALYNZIQ dominates the PKU treatment market, accounting for the largest share of 67.9% in 2024. The drug is expected to grow at a significant Compound Annual Growth Rate (CAGR) over the forecast period. The global PKU treatment market, valued at $518.7 million in 2024, is projected to grow at a CAGR of 9.4% from 2025 to 2030[4].

Parenteral Administration and Efficacy

PALYNZIQ is administered parenterally, which allows for rapid and complete drug absorption, bypassing gastrointestinal variability. This route of administration enhances treatment efficacy, a key factor driving the growth of the parenteral segment in the PKU treatment market. The drug's ability to maintain mean blood phenylalanine levels compared to baseline, with a roughly 60% improvement over placebo, underscores its clinical efficacy[1][4].

Regional Market Dynamics

The North American market holds the largest share of the PKU treatment market, driven by enhanced newborn screening programs, advances in treatment options, and government initiatives supporting research and early detection. The well-established healthcare infrastructure and funding options in this region facilitate patient access to treatments like PALYNZIQ[4].

Challenges and Mitigation Strategies

Despite its success, PALYNZIQ faces challenges such as the risk of anaphylaxis, which led to the implementation of a Risk Evaluation and Mitigation Strategy (REMS) program. BioMarin's strategy to launch the drug at experienced sites and expand gradually has helped mitigate these risks. The company leverages its commercial experience with Kuvan to support the launch of PALYNZIQ, which is expected to cover about 85% of the U.S. PKU market[1].

Financial Outlook and Projections

Investment bank Leerink projects that PALYNZIQ will achieve peak annual sales of more than $500 million by 2029. BioMarin's overall financial performance has been robust, with total revenues for 2023 reaching $2.42 billion, a 15% year-over-year increase. The company anticipates double-digit total revenue growth and significant non-GAAP operating margin expansion in 2024[2][5].

Key Takeaways

  • Regulatory Approval: PALYNZIQ received FDA approval in May 2018 for treating adults with PKU.
  • Market Dominance: PALYNZIQ accounts for the largest share of the PKU treatment market and is expected to grow significantly.
  • Financial Performance: The drug has shown steady revenue growth since its launch.
  • Parenteral Administration: The parenteral route enhances treatment efficacy and drives market growth.
  • Regional Dynamics: North America is the largest market, driven by advanced healthcare infrastructure and government initiatives.
  • Challenges and Mitigation: BioMarin addresses anaphylaxis risks through a REMS program and strategic launch plans.

FAQs

What is PALYNZIQ used for?

PALYNZIQ (pegvaliase) is used to treat adults with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol per liter on existing management regimens.

When was PALYNZIQ approved by the FDA?

PALYNZIQ was approved by the FDA in May 2018.

What is the wholesale acquisition cost of PALYNZIQ?

The wholesale acquisition cost of PALYNZIQ is $192,000.

How does PALYNZIQ compare to Kuvan in terms of market position?

PALYNZIQ is positioned as a premium product compared to Kuvan, with a higher wholesale acquisition cost and targeted at patients with uncontrolled blood phenylalanine levels.

What are the projected peak annual sales for PALYNZIQ?

Investment bank Leerink projects that PALYNZIQ will achieve peak annual sales of more than $500 million by 2029.

Sources

  1. BioPharma Dive: "BioMarin cleared to bring new PKU drug to market" - May 25, 2018
  2. BioSpace: "BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24 Percent" - October 26, 2022
  3. BioMarin: "BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results" - February 2020
  4. Grand View Research: "Phenylketonuria Treatment Market | Industry Report, 2030"
  5. BioMarin Investors: "BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024" - February 22, 2024
Last updated: 2024-12-17

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.